# X-Therma

> X-Therma develops synthetic antifreeze-inspired preservation media and portable transport devices for cells, tissues and organs. Its commercial cell-preservation products and preclinical organ-transport work aim to give living medicines more usable time between manufacture or donation and treatment.

- **Founded:** 2014
- **Headquarters:** Hercules, United States
- **Founders:** Xiaoxi Wei (CEO and Co-founder), Mark Kline (COO and Co-founder; previously CTO)
- **Products:** XT-Thrive®, XT-ViVo®, TimeSeal®, XT-NoVo® & TimeSeal® platform
- **Notable:** 2019 mouse-heart transplantation milestone reported by the company., 2022 FDA Breakthrough Device designation for XT-ViVo and TimeSeal., 2024 XT-Thrive Drug Master File acceptance and GMP commercial readiness.

## Products & services

- **XT-Thrive®** — cGMP-grade, chemically defined, DMSO-, serum- and protein-free medium for mammalian cell and tissue cryopreservation at -70°C to -196°C. FDA Drug Master File accepted in 2024.
- **XT-ViVo®** — Synthetic antifreeze-inspired organ preservation solution paired with TimeSeal. FDA Breakthrough-designated in 2022 for intended kidney preservation up to 120 hours; animal results do not establish human clinical efficacy.
- **TimeSeal®** — Portable, sensor-equipped transporter designed for stable subzero storage without external power or perfusion during transport.
- **XT-NoVo® & TimeSeal® platform** — Commercially launched June 10, 2026. Company-described DMSO-free, ice-free preservation at -5°C for cells, tissues and engineered constructs for up to five days, subject to application validation.

## Achievements

- 2019 mouse-heart transplantation milestone reported by the company.
- 2022 FDA Breakthrough Device designation for XT-ViVo and TimeSeal.
- 2024 XT-Thrive Drug Master File acceptance and GMP commercial readiness.
- Five transatlantic pig-kidney journeys reported in October 2024, with 48-72-hour preservation.
- A separate pig transplantation proof of concept reported normal kidney function throughout a 200-day observation period after 72-hour preservation.
- June 2026 commercial launch of XT-NoVo and TimeSeal.

## Latest updates

- **2026-06** — XT-NoVo and TimeSeal commercial launch announced June 10.
- **2025-09** — The Molecular Foundry published an interview discussing X-Therma’s peptoid ice-control research and manufacturing scale.
- **2025-07** — Company reported participation in the June 11 Hopkins on the Hill event.
- **2025-06** — Neil Warma joined the board, announced June 10.

## Links

- Website: https://x-therma.com/
- LinkedIn: https://www.linkedin.com/company/x-therma-inc-/
- Twitter/X: https://twitter.com/x_therma
- Facebook: https://facebook.com/xtherma/

---

Profile page: https://yespress.io/x-therma
Published by YesPress — https://yespress.io
Last updated: 2026-10-02